ClinicalTrials.gg
Active, not recruitingNCT07215468VISTAUpdated Aug 6, 2026

HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study

A Phase 2 interventional study of TMB-365 and TMB-380 in HIV -1 Infection, sponsored by TaiMed Biologics Inc.. Active, not recruiting at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by TaiMed Biologics Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry. This study is designed to test the combination of the antibodies as maintenance therapy in HIV infected suppressed individuals discontinuing oral cART for 48 weeks.

Researchers will compare TMB-365/TMB-380 given IV every 8 weeks to continuation of daily oral cART to see if TMB-365/TMB-380 can also maintain viral suppression.

Participants will:

  1. Receive TMB-365/TMB-380 infusion or take oral cART as scheduled for 48 weeks
  2. Visit the clinic as schedule for checkups and tests
02

Conditions studied

  • HIV -1 Infection

Keywords

  • HIV-1 maintenance treatment
  • HIV switch therapy
  • Broadly neutralizing antibody (bNAb)
  • HIV post-attachment inhibitor
  • monoclonal antibody (mAb)
03

In context

Lead sponsor

TaiMed Biologics Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age on the day of Screening.
  2. Asymptomatic -1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by Geenius™ or a second antibody test by a method other than the initial rapid HIV and/or E/CIA test, or by HIV-1 antigen, plasma HIV-1 RNA viral load at or prior to screening.
  3. On continuous suppressive cART for at least 6 months prior to Screening with one documented HIV-1 RNA level \<50 copies/mL within 6 months of Screening. Continuous cART is defined as no interruptions greater than 3 consecutive days. cART is defined as a DHHS recommended regimen. Study participants should be on a stable oral regimen for at least 3 months prior to Screening.
  4. Screening plasma HIV-1 RNA \< 50 copies/mL
  5. >350 cells/mm3
  6. Laboratory values obtained within 35 days prior to the first dose:

    • ≥ 10.0 g/dL
    • count ≥ 100,000/mm3
    • ≥ 1,000/mm3
    • Serum (AST) and alanine aminotransferase (ALT) \< 1.5 x (ULN)
    • (CrCl) of ≥ 50 mL/min
  7. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.
  8. In the opinion of the principal investigator or designee, has understood the information provided; written needs to be given before any study-related procedures are performed.
  9. Persons of sexually active with a partner who can impregnate them, must agree to use one effective method of from the time of signing the consent to completion of the study, and agree to pregnancy testing as per the Schedule of Events and Procedures. Persons of childbearing potential are participants born female who are not surgically sterile (no history of bilateral tubal ligation, hysterectomy, or bilateral salpingo-oophorectomy), are not (at least one year without menses), and are not otherwise sterile by medical evaluation.

Exclusion criteria

Exclusion Criteria:

  1. History of receipt of any monoclonal antibody for any treatment, including bNAbs, whether naturally occurring, such as VRC01, or modified, such as VRC07-523LS.
  2. History of receipt of any long-acting ARV for treatment or prevention of ( and commercial), including but not limited to cabotegravir/rilpivirine combination, lenacapavir, and islatravir.
  3. Pregnant, planning a pregnancy during the trial period, or lactating.
  4. Known allergy/sensitivity or any to components of the study drug or its formulation, or known allergy to a MAb.
  5. History of severe allergic reactions to medications, vaccinations, or monoclonal antibody therapy for other conditions such as COVID.
  6. Major psychiatric illness including any history of schizophrenia or severe psychosis, uncontrolled bipolar disorder requiring acute therapy, or suicide attempt in the previous three years.
  7. Serious illness requiring systemic treatment and/or hospitalization within 21 days prior to Baseline.
  8. Receipt of immunomodulatory agents (e.g., interleukins, interferons, cyclosporine, high dose systemic ), HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 180 days prior to Baseline.
  9. Any chronic or acute medical condition, including chronic infection, chronic infection with viremia, drug use and alcohol abuse, which in the opinion of the investigator would interfere with evaluation of the study drug.
  10. Lack of adequate venous access.
  11. Individuals who have experienced virologic failure during treatment with two or more cART treatment regimens and those being treated with regimens containing either ibalizumab, enfuvirtide, maraviroc, or fostemsavir. Note that a change in treatment regimen for intolerance does not meet criteria for treatment failure.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Combination of TMB-365 and TMB-380 antibodies via IV infusions

    Participants will receive an IV infusion of the combination of TMB-365 and TMB-380 each every 8 weeks.

    Drug: TMB-365 · Drug: TMB-380

  • Active comparator
    Baseline oral cART

    Participants will continue suppressive daily oral cART

    Drug: Baseline ART

Interventions

  • DrugTMB-365

    A monoclonal antibody acts as a HIV post-attachment inhibitor to be given intravenously

  • A broadly neutralizing antibody (bNAb) against HIV to be given intravenously

    Also known as: VRC07-523LS

  • DrugBaseline ART

    Baseline ART to be taken daily and orally

06

What researchers measure

Primary outcomes

  1. Antiviral activity of TMB-365 and TMB-380 as maintenance therapy compared to daily oral cART

    % of subjects with plasma HIV-1 RNA greater than or equal to 50 c/mL at week 48 by snapshot analysis as defined by US FDA

    Time frame: Week 48

Secondary outcomes

  1. Number of participants who experience protocol-defined virologic failure

    Virologic failure is defined as two consecutive plasma HIV-1 RNA levels ≥200 copies/mL obtained at least 2 weeks apart.

    Time frame: 48 weeks

  2. Pharmacokinetic profile of TMB-365

    Mean trough concentrations for TMB-365 in Experimental Arm

    Time frame: Week 48

  3. Pharmacokinetic profile of TMB-380

    Mean trough concentrations for TMB-380 in Experimental Arm

    Time frame: Week 48

  4. Safety of maintenance treatment regimen

    Number of participants experience grade 3, grade 4, or serious adverse reactions related study treatment.

    Time frame: 48 weeks

  5. Immune effects of maintenance therapy

    Changes in CD4+ cell counts (cells/mm3) from baseline to Week 48

    Time frame: 48 weeks

07

Study locations

10 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for May 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2025
First posted
Oct 10, 2025
StartActual
Dec 16, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07215468
Lead sponsor
TaiMed Biologics Inc.
Responsible party
Sponsor
First posted
Oct 10, 2025
Start date
Dec 16, 2025
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Aug 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VRC07-523LS

Start the discussion